YM BioSciences Inc.
5045 Orbitor Drive
Suite 400 Building 11
Mississauga,
ON L4W 4Y4
Canada - Map
Phone: 905-629-9761
Fax: 905-629-4959
Web Site: http://www.ymbiosciences.com
| YM Biosciences Inc., a biopharmaceutical company, engages in the licensing and commercialization of drug products and technologies primarily for the treatment of cancer or cancer-related conditions worldwide. Its approved product Nimotuzumab, a humanized monoclonal antibody that targets the epidermal growth factor receptor, is used for the treatment nasopharyngeal carcinomas, head and neck cancer, refractory children glioma, adult glioma, and stage III/IV glioma. The company is also developing Nimotuzumab for various other epithelial cancers; and AeroLEF, a proprietary formulation of free and liposome-encapsulated fentanyl administered by pulmonary inhalation for the treatment of severe and moderate acute pain, including cancer pain. In addition, its other product candidates include TGFa and HER-1, the anti-cancer vaccines. The company was formerly known as York Medical Inc. and changed its name to YM Biosciences Inc. in February 2001. YM Biosciences was founded in 1994 and is headquartered in Mississauga, Canada. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. David G.P. Allan , 68
Chairman, Chief Exec. Officer and Pres of YM BioSciences USA Inc |
N/A
| N/A | Mr. Leonard Vernon B.Sc., CA, 66
Principal Financial Officer, Principal Accounting Officer, VP of Fin. & Admin. and Sec. |
N/A
| N/A | Mr. Vincent A. Salvatori Ph.D., 58
Chief Exec. Officer of CIMYM BioSciences Inc and Pres of CIMYM BioSciences Inc |
N/A
| N/A | Dr. Ali Raza , 52
Pres of AeroLEF Division |
$
422.00K | N/A | Mr. Sean Thompson B.Sc., 44
VP of Strategic Projects and Corp. Devel. |
$
178.00K | N/A |
|
|
|
Dollar amounts are as of
31-Dec-09
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.11% Nasdaq 
0.01%
Profile
